Introduction
Angiogenesis, the formation of new blood vessels from the pre-existing vasculature, is essential for vessel formation during embryonic development and organogenesis. However, enhanced neovascularization is a contributing factor in the progression of rheumatoid arthritis, psoriasis, diabetic retinopathy and solid tumor growth (Folkman, 1995; Carmeliet and Jain, 2000) . Among the many factors identified to play a role in angiogenesis, vascular endothelial growth factor (VEGF) is of paramount importance, as demonstrated by early embryonic lethality due to abnormalities in vascular development in mice deficient in VEGF or its receptors (Fong et al., 1995; Shalaby et al., 1995; Carmeliet et al., 1996; Ferrara et al., 1996) . VEGF receptors, VEGFR-1 and VEGFR-2, are restricted in their tissue distribution primarily to endothelial cells (Yancopoulos et al., 2000) . The binding of VEGF to its cognate receptors induces dimerization and subsequent phosphorylation of the receptors leading to the activation of several intracellular signaling molecules such as phosphatidylinositol 3-kinase (PI-3K), phospholipase Cg (PLCg), protein kinase C (PKC), nitric oxide (NO) synthase, mitogen-activated protein kinases (MAPKs) and focal adhesion kinases (FAKs) (Karkkainen and Petrova, 2000) .
The two members of the FAK family, FAK and related focal adhesion tyrosine kinase/proline-rich tyrosine kinase 2 (RAFTK/Pyk2), are nonreceptor, proline-rich protein tyrosine kinases. A high level of sequence homology and similar structural organization exists between FAK and RAFTK/Pyk2; however, the cellular distribution of each molecule is different. FAK is mainly localized to focal adhesions and is regulated by integrin-mediated cell adhesion. In contrast, RAFTK/ Pyk2 is distributed diffusely throughout the cytoplasm and shows greater activation in response to soluble factors and increases in intracellular calcium (Zheng et al., 1998) . The activation of the autophosphorylation sites of FAK and RAFTK/Pyk2, Tyr 397 and Tyr 402, respectively, allows the binding of the SH2 domain of the Src family kinases, which further phosphorylates tyrosine residues in the C-terminus (Hanks and Polte, 1997; Zheng et al., 1998; Avraham et al., 2000; Parsons et al., 2000) resulting in the full activation of FAK and RAFTK/Pyk2.
MAPKs are serine/threonine protein kinases that transmit signals from the membrane to the nucleus in response to growth factors and cellular stress. Three principal isoforms of MAPKs exist: extracellular signalregulated kinase (ERK), c-jun NH 2 -terminal kinase (JNK) and p38 MAPK (p38). Activation of MAPKs occurs through phosphorylation of threonine and tyrosine residues of the Thr-X-Tyr motif by MAPK kinases (MEKs). Different upstream kinases are responsible for the activation of each MAPK. For example, ERK is phosphorylated by MEK1 and MEK2, while p38 is phosphorylated primarily by MEK3 and MEK6 (Widmann et al., 1999) .
Activation of ERK by VEGF is implicated in cell proliferation, while VEGF-induced activation of p38 is correlated with changes in permeability and migration (Rousseau et al., 1997; Issbrucker et al., 2003) . In addition, the antiapoptotic signals generated by VEGFmediated activation of the PI3K/Akt pathway can be balanced by crosstalk with the p38 pathway, thereby establishing appropriate survival signals (Gratton et al., 2001) . Genetic studies indicate that a null mutation of p38a, MEKK3, a potential upstream activator, or myocyte enhance factor 2C (MEF2C), a downstream effector, all result in embryonic lethality due to defects in vascularization (Lin et al., 1998; Bi et al., 1999; Mudgett et al., 2000; Yang et al., 2000) . Collectively, these data provide support for an important role of p38 modulation in the regulation of the neovascularization response.
Previous studies have identified PLC and Ras as important upstream regulators of ERK in response to VEGF (Wu et al., 2000; Meadows et al., 2001) . However, the molecular mechanism governing the activation of p38 in response to VEGF remains undefined. FAK and RAFTK/Pyk2, members of the FAK family, are attractive potential regulators of p38 activation since FAK has been implicated in VEGFinduced migration (Avraham et al., 2003) and a role for RAFTK/Pyk2 in regulating p38 has been demonstrated in several nonendothelial cell systems Pandey et al., 1999; Sorokin et al., 2001) . Another attractive target as a modulator of p38 is Src, since previous studies have demonstrated its activation in response to VEGF (He et al., 1999; Suarez and BallmerHofer, 2001 ) and it is reported to regulate VEGFmediated migration and permeability changes, similar to p38 (Eliceiri et al., 1999; Liu et al., 2001; Paul et al., 2001) . In the present study, we investigate the upstream regulators of p38 activation in response to VEGF in primary human endothelial cells. Our data demonstrate that genetic disruption of p38 results in a loss of cellular migration in response to VEGF. Activation of p38 is dependent upon extracellular calcium, RAFTK/Pyk2 and Src. Consistent with these results, we find that RAFTK/Pyk2 and Src are also essential for migration of endothelial cells in response to VEGF, thereby establishing a novel signal transduction network likely to play an important role in the angiogenic response.
Results
One critical aspect of angiogenesis is the migration of endothelial cells (Karkkainen and Petrova, 2000) . Previous studies have identified p38 MAPK as an important regulator of VEGF-induced migration of endothelial cells through the use of the pharmacological inhibitor of p38, SB203580 (Rousseau et al., 1997) . However, various studies have revealed that this p38 inhibitor can have 'nonspecific' inhibitory effects on other signaling molecules including PI3K, transforming growth factor b (TGFb) receptor and JNK, while other studies show that it can activate the Raf/ERK pathway (Kalmes et al., 1999; Lian et al., 1999; Davies et al., 2000; Ishii et al., 2001; Laping et al., 2002) . We sought to test the role of p38 in the VEGF-induced migratory response using a genetic approach and constructed a Flag-tagged, dominant-negative p38 (DNp38) adenovirus, which has a mutation in the phosphorylation motif. Human umbilical vein endothelial cells (HUVECs) infected with the DNp38 adenovirus showed expression of the Flag-tag on the DNp38 and significant decreases in the phosphorylation levels of two downstream effectors of p38, heat-shock protein 27 (Hsp27) and activating transcription factor 2 (ATF2) (Figure 1a ). Total Hsp27 levels were used to show equal loading of protein ( Figure 1a ). These data demonstrated the effectiveness of the construct at inhibiting p38 activity. Subsequently, we seeded DNp38-infected cells and SB203580-treated cells on transwell filters and placed VEGF in the lower well to induce migration. Inhibition of p38 by either genetic or pharmacological means resulted in a marked reduction in cell migration (Figure 1b) .
Initially, time course experiments were performed to understand the temporal relationship between VEGF and p38 in endothelial cells and found peak activation of p38 MAPK at 15 min that returns to basal levels by 1 h Figure 1 Inhibition of p38 activity inhibits VEGF-induced cell migration. (a) HUVECs infected with GFP or DNp38 adenovirus were serum starved prior to stimulation with VEGF (50 ng/ml). The cell lysates were analysed by probing Western blots with pHsp27, Hsp27, pATF2 and FLAG antibodies. (b). Serum-starved HUVECs were either infected with GFP or DNp38 adenovirus or pretreated with SB203580 (5 mM) or a vehicle control for 30 min prior to seeding on a transwell filter with VEGF (25 ng/ml) in the lower chamber to induce cell migration. Representative data of one experiment performed at least three times are presented
(data not shown); therefore, a 15-min time point was used for all subsequent studies. Using a range of pharmacological inhibitors, we found no evidence that implicated PKC, PI3K or NO synthase in the regulation of p38 activation (data not shown). Similarly, infection with adenoviruses coding for dominant-negative GTPases including Ras, Rac, Rho and Cdc42 were without effect (data not shown) (Meadows et al., 2001) . Therefore, the activation of p38 in response to VEGF is independent of these signaling molecules. Given the previously proposed role of FAK in endothelial cell migration (Avraham et al., 2003) , we sought to understand the role of FAK and the related kinase, RAFTK/Pyk2, in VEGF-induced activation of p38. The stimulation of HUVECs with VEGF induced the phosphorylation of Tyr 397 on FAK and Tyr 402 on RAFTK/Pyk2, their respective autophosphorylation sites ( Figure 2a ). Equal protein loading was demonstrated by total FAK levels ( Figure 2a ). These data confirmed that activation of FAK and RAFTK/Pyk2 occurred in response to VEGF, in our system. Subsequently, we used a genetic approach to investigate the role of FAK and RAFTK/Pyk2 in the VEGF-induced activation of p38 MAPK. An endogenously expressed C-terminal splice variant of FAK, FAK-related nonkinase (FRNK), which competitively inhibits endogenous FAK when overexpressed, was used to inhibit FAK activity (Parsons et al., 2000) . We found that expression of FRNK had no affect on total protein levels as demonstrated by total FAK, and had no affect on the activation of p38 MAPK ( Figure 2b) ; however, the phosphorylation of Tyr 397 of FAK was reduced significantly under these conditions (Figure 2c ). To investigate a potential role of RAFTK/Pyk2, we used an adenovirus coding for a dominant-negative RAFTK/ Pyk2 containing a point mutation of residue 402 from tyrosine to phenylalanine, rendering it unable to become autophosphorylated or bind Src kinases. These experiments revealed that the RAFTK/Pyk2 mutant inhibited the activation of p38 MAPK in response to VEGF (Figure 2d ). Interestingly, interfering with RAFTK/ Pyk2 signaling had no affect on VEGF-induced activation of ERK (Figure 2e ).
RAFTK/Pyk2 can be activated in response to calcium in vascular endothelial cells (Keogh et al., 2002) ; therefore, we sought to better understand the relationship between calcium and p38 activation. VEGF can induce an influx of extracellular calcium into the cell through membrane calcium channels (Criscuolo et al., 1989; Pocock et al., 2000; Garnier-Raveaud et al., 2001) . Chelating extracellular calcium, by a 5 s pretreatment with EGTA, abolished the VEGF-induced activation of Figure 2 RAFTK/Pyk2, but not FAK, is required for VEGF stimulation of p38 MAPK. (a) HUVECs were serum starved overnight prior to stimulation with VEGF (100 ng/ml) for 2 min. Cell lysates were analysed by probing Western blots with pPyk2 402, pFAK397, or FAK antibodies. (b) HUVECs were infected with GFP or FRNK adenovirus to competitively inhibit FAK activation. Cells were serum starved prior to stimulation with VEGF (50 ng/ml). Whole-cell lysates were probed with pp38, pFAK397 and FAK antibodies. (c) HUVECs were infected with GFP or FRNK adenovirus. Cells were serum starved prior to stimulation with VEGF (50 ng/ml) for 15 min. Whole-cell lysates were probed with pFAK397 and FAK antibodies. (d, e) HUVECs were infected with a GFP or a dominant-negative RAFTK/Pyk2 adenovirus overnight. Cells were serum starved prior to stimulation with VEGF (50 ng/ml). The cell lysates were analysed by probing Western blots with pp38, p38 or RAFTK/Pyk2 antibodies (d) and active ERK (pERK) or ERK (e). Representative data are presented from experiments performed two additional times Figure 3 ERK activity is dependent on PLC, while p38 activity is dependent on extracellular calcium. (a) Serum-starved HUVECs were pretreated with the calcium chelator, EGTA (5 mM), for 5 s prior to stimulation with VEGF (50 ng/ml) for 15 min or with the calcium ionophore, A23187, (1 mM) for a total of 10 min as indicated. The cell lysates were analysed by probing Western blots with antibodies specific for pp38 and p38. (b) Serum-starved HUVECs were pretreated with EGTA (5 mM) for 5 s prior to stimulation with VEGF (50 ng/ml) for 2 min. Western blots were probed with pPyk2 402 and Pyk2 antibodies. (c, d) Serum-starved HUVECs were pretreated with vehicle control, a PLC inhibitor, U73122 (10 mM) or its inactive analog, U73343 (10 mM), for 30 min prior to VEGF (50 ng/ml) treatment. Whole-cell lysates were probed with antibodies specific for pp38 or p38 (c) and PERK or ERK (d). All blots are representative of three separate experiments VEGF-mediated p38 activation M McMullen et al p38 MAPK in endothelial cells (Figure 3a) . Importantly, we found that pretreatment with EGTA was not sufficient to inhibit the VEGF-induced phosphorylation of Tyr 402 on RAFTK/Pyk2 (Figure 3b ). These data suggest that the influx in extracellular calcium is required for activation of the p38 signaling pathway; however, it appears that a role exists for calcium independent of activating RAFTK/Pyk2.
Increasing intracellular calcium levels by treatment with the calcium ionophore, A23187, is sufficient to activate RAFTK/Pyk2 in endothelial cells (Rikitake et al., 2001) . To determine if increases in calcium levels within the cell were sufficient to activate p38 MAPK, we treated serum-starved cells with 1 mM calcium ionophore, A23187. Under these conditions, we found p38 activation levels comparable to those induced by VEGF (Figure 3a) , suggesting that calcium may be a triggering signal for p38 activation. Also, pretreatment with EGTA inhibited the p38 activity induced by A23187 (Figure 3a) .
VEGF induces increases in intracellular calcium that are largely generated through activation of PLC (Pocock and Bates, 2001) . Importantly, activation of PLC by VEGF is dependent upon extracellular calcium (Seymour et al., 1996) . We reasoned that activation of PLC might be required for p38 activation and tested this by pretreating cells with 10 mM U73122, a PLC inhibitor, or 10 mM U73343, an inactive analog, prior to VEGF stimulation. Western blot analysis demonstrated that U73122 had no affect on p38 MAPK activation (Figure 3c ). In contrast, ERK activation, as previously reported (Pocock and Bates, 2001) , was inhibited completely by U73122 (Figure 3d ), suggesting that ERK requires the release of intracellular calcium stores (Karkkainen and Petrova, 2000) following the production of inositol triphosphate (IP3) and diacylglycerol (DAG) by PLC. As expected, cells pretreated with the inactive analog showed no inhibition (Figure 3c, d) .
Src family kinases are known to physically associate with RAFTK/Pyk2 (Avraham et al., 2000) ; therefore, we examined the role of Src kinases in the VEGFinduced activation of p38. First, we utilized two pharmacological inhibitors of the Src family tyrosine kinases, PP1 and PP2. In parallel experiments, a vehicle control and the inactive analog PP3 were used to address the specificity of the inhibitors. Pretreatment of HUVECs with 3 mM PP1 and 10 mM PP2 inhibited the activation of p38 MAPK in response to VEGF treatment, while PP3 had no affect (Figure 4a ). We confirmed these findings using a genetic approach in which we infected endothelial cells with a kinase-inactive Src (KI Src) adenovirus. This construct contains a point mutation of lysine 297 to arginine, which renders Src inactive. Infection of HUVECs with KI Src prevented the activation of p38 MAPK (Figure 4b ). Collectively, these data demonstrate a critical role for Src activity in the phosphorylation of p38 MAPK in response to VEGF stimulation.
If Src and RAFTK/Pyk2 are critical upstream regulators of p38 activation in response to VEGF, it would be predicted that inhibition of either would interfere with migration since p38 is necessary for VEGF-induced migration. We investigated the role of Src and RAFTK/Pyk2 in regulating VEGF-induced migration and found that pretreatment of cells with PP1 markedly reduced the number of migrating cells (Figure 5a) . Similarly, inhibition of RAFTK/Pyk2 by Figure 4 Inhibition of Src family kinases prevents the activation of p38 MAPK in response to VEGF. (a) Serum-starved HUVECs were pretreated with inhibitors specific for the Src family kinases, PP1 (3 mM) and PP2 (10 mM), or the inactive analog, PP3 (10 mM), for 30 min prior to VEGF (50 ng/ml) stimulation for 15 min. Western blots were probed with pp38 and p38 antibodies. (b) HUVECs were infected with a GFP or a KI Src adenovirus overnight. Cells were serum starved prior to stimulation with VEGF. The cell lysates were analysed by probing Western blots with pp38 and p38 antibodies. Representative blots are shown of experiments performed at least three times (Figure 5b) . Collectively, these data indicate an important role of upstream regulators of p38 MAPK in migration similar to the importance of p38.
Discussion
Collectively, our results provide evidence that activation of p38 by VEGF requires RAFTK/Pyk2, Src and calcium. This signal transduction cascade is an integral part of the VEGF-induced migration response. These data, summarized in Figure 6 , clarify for the first time, the signals responsible for the regulation of p38 activity in response to stimulation of endothelial cells with VEGF.
RAFTK/Pyk2 has been linked to p38 activation in other cell types Pandey et al., 1999; Sorokin et al., 2001) and to migration (McShan et al., 2002; Avraham et al., 2003) ; however, our results are the first to link RAFTK/Pyk2 activation by VEGF to a downstream biochemical event, such as p38 activation. Furthermore, these data provide a linkage between the control of cellular migration by RAFTK/Pyk2 and Src and the control of cellular migration by p38 MAPK. However, we observe only partial inhibition of cell migration with DNp38, whereas inhibition of RAFTK/ Pyk2 or Src completely abolished migration. This may be due to the concomitant inhibition of other molecules that are controlled by RAFTK/Pyk2 and Src. One example might be Akt that has been shown to be regulated by RAFTK/Pyk2 (Sarkar et al., 2002) and Src (Jiang and Qiu, 2003) and has been shown to modulate endothelial cell migration in response to NO (Kawasaki et al., 2003) . Another possible candidate pathway would be p130 cas /Crk, which has been implicated in endothelial cell migration in response to ephrin-B1 (Nagashima et al., 2002) .
The biochemical linkage we have found between Src activity and p38 activation may also be critical for understanding another of the biological activities of VEGF, transcellular permeability. VEGF is known to potently induce permeability, which is believed to play an important role in the neovascularization of tumors and wounds (Dvorak et al., 1995) . In fact, separate investigations have linked both Src and p38 to VEGFinduced increases in permeability (Eliceiri et al., 1999; Paul et al., 2001; Issbrucker et al., 2003) . Our data suggest that these two biochemical pathways may be working in a coordinated and dependent fashion to regulate endothelial barrier function. It will be of interest to determine if the mechanisms responsible for modulating the migration response downstream of p38 in subconfluent cells are the same as those required for the modulation of transcellular permeability in confluent monolayers.
Several of our experiments elucidate important differences between the activation of p38 and ERK in response to VEGF stimulation. First, expression of the RAFTK/Pyk2 Y402F mutant that lacks the autophosphorylation and Src binding site interfered with activation of p38 and cell migration; however, it had no affect on ERK activity. Next, we identified an influx of extracellular calcium, but not PLC activation as a requirement for p38 activation. In contrast, PLC activity was essential for activation of ERK. These results provide evidence of a potential bifurcation in the upstream mediators of the activation of MAPKs, p38 and ERK, at the level of PLC and RAFTK/Pyk2 activation.
VEGF induces a biphasic increase in intracellular calcium (Faehling et al., 2002) , although the kinetics and mechanism of this response may be quite complex. The initial peak is sharp but transient and is believed to be dependent on the activation of PLC and release of IP 3 -gated intracellular stores, which lead to the activation of ERK likely also involving PKC (Karkkainen and Petrova, 2000) . In contrast to agents like thrombin, the VEGF-mediated activation of PLC, and subsequent IP3-mediated release, is dependent upon an initial influx of calcium from the extracellular space (Seymour et al., 1996) . The second phase of the heightened calcium concentration is a sustained plateau phase maintained by an influx of extracellular calcium through membrane calcium channels, albeit at much lower levels than the initial peak (Faehling et al., 2002) . There are also data suggesting that these pools of calcium may be spatially distinct (Huser and Blatter, 1997) . Our data suggest that the activation of p38 depends on extracellular calcium, but not PLC, in contrast to ERK activation. However, the data also imply a role for calcium that is independent of RAFTK/Pyk2 activation. Given the complexity of calcium signaling in response to VEGF, Figure 6 A model for the activation of p38 MAPK in response to VEGF. Activation of VEGFRs can trigger the activation of RAFTK/Pyk2 and Src. Subsequently, Src is recruited to its known binding site at Tyr 402 of RAFTK/Pyk2, and phosphorylates the C-terminal tyrosine residues of RAFTK/Pyk2. This translates into increased activation of p38 MAPK and ultimately regulation of endothelial cell migration and permeability through a mechanism that remains to be defined. VEGF also induces an influx of extracellular calcium, which is necessary for p38 activity. In contrast, the activation of PLC in response to VEGF treatment leads to the release of IP 3 -gated intracellular calcium stores and subsequent activation of ERK, which controls cell proliferation VEGF-mediated p38 activation M McMullen et al elucidation of the precise mechanism by which calcium may control the p38 response will require many additional studies. However, it is tempting to speculate that the biphasic and distinct mechanisms of calcium entry may provide different spatially restricted signaling cues perhaps to regulators such as calmodulin or enzymes such as CAM-Kinase, which are known to be spatially organized in some cell types (Toutenhoofd and Strehler, 2000; Hudmon and Schulman, 2002) , particularly as these molecules have previously been implicated in p38 activation (Blanquet et al., 2003; Zahalka et al., 2003) .
Evidence in the existing literature has indicated that both ERK and p38 are important for the formation of blood vessels. Genetic knockouts of p38, MEKK3 and MEF2C (Lin et al., 1998; Bi et al., 1999; Mudgett et al., 2000; Yang et al., 2000) all implicate an important role for p38 in developmental angiogenesis. Similarly, knockouts of MEK1, B-Raf and Raf-1, upstream activators of ERK, lead to embryonic lethality due to defects in the formation of the vasculature (Wojnowski et al., 1997; Giroux et al., 1999; Huser et al., 2001) . Thus, both MAPK pathways appear to be essential for angiogenesis. Notably, the downstream cellular phenotypes controlled by each of these phenotypes is different: ERK has no affect on cell migration but is critical for proliferation (Meadows et al., 2001) , while our data as well as evidence in the existing literature indicate an important role for p38 in endothelial cell migration (Rousseau et al., 1997) and permeability (Issbrucker et al., 2003) but no role in proliferation. It is interesting to speculate that these separable signaling modules may be an important mechanism to control those elements of the angiogenic phenotype that are manifest at any one time in response to VEGF and thereby preserve a coordinated angiogenic response. Congruent with this hypothesis, a recent report has suggested that p38 may function as a binary switch to negatively regulate survival and positively regulate permeability (Issbrucker et al., 2003) , a potentially important phenotype for early vessel remodeling (Yancopoulos et al., 2000) . However, the biochemical mechanism of this switching remains undefined. The identification of upstream modulators of p38 activity and the ability to genetically inhibit p38 will provide an insight into the role of p38 MAPK in regulating the angiogenic response.
Materials and methods

Materials
VEGF was obtained from the NCI developmental therapeutics program. PP1, Wortmannin, LY-294002, GF-109203X, L-NAME, U-73122 and U-73343 were obtained from BioMol (Plymouth Meeting, PA, USA). PP2 and PP3 were obtained from CalBiochem (La Jolla, CA, USA). Rabbit polyclonal anti-phospho-p38, anti-p38 antibodies, anti-phospho-Hsp27, anti-phospho-ATF2, anti-phospho-Pyk2-Tyr402, anti-Pyk2 and mouse monoclonal anti-Hsp27 antibodies were obtained from Cell Signaling Technology (Beverly, MA, USA). Mouse monoclonal anti-phospho-ERK, rabbit polyclonal anti-ERK and goat polyclonal anti-RAFTK/Pyk2 antibodies were obtained from Santa Cruz Biotechnologies (Santa Cruz, CA, USA). Rabbit polyclonal anti-phospho-FAK-Tyr397 antibody was obtained from BioSource International (Camarillo, CA, USA). Rabbit polyclonal anti-FAK antibody was obtained from Upstate Biotechnology (Lake Placid, NY, USA).
Generation of recombinant adenoviruses
The cDNAs for Cdc42 N17 and Rac N17 were a generous gift of Allen Hall (University College London). The cDNA for Rho N19 was a generous gift of G Bokoch (The Scripps Research Institute). The cDNA for RAFTK/Pyk2 402 was a generous gift of Hava Avraham (Harvard Medical School). The cDNA for DNp38 was a generous gift of Roger Davis (University of Massachusetts Medical School). The KI-Src cDNA was purchased from UpState Biotechnology (Lake Placid, NY, USA), while the FRNK cDNA was cloned from HEK293 cells using RT-PCR (primers available upon request). cDNAs were cloned into either the pShuttle or pAdtrack shuttle vectors and viruses were generated essentially as described (He et al., 1998; Meadows et al., 2001) . All adenoviruses were used at MOIs of 10-50.
Cell culture
HUVECs were supplied by VEC Technologies (Troy, NY, USA) through the NCI angiogenesis resource center. These cells were maintained in M199 media containing 20% FBS, 1% penicillin/streptomycin, 10 mg/ml heparin and 50 mg/ml endothelial cell growth supplement (Collaborative Biomedical Products). The cells were cultured at 371C in a humidified 5% CO 2 environment on tissue culture dishes coated with 0.2% gelatin. For experiments requiring serum-deprivation, MCDB-131 supplemented with 1% penicillin/streptomycin and 2 mM L-glutamine was used as indicated.
Western blotting
HUVECs were grown to near confluence in 35-mm or 60-mm dishes. Cells were infected overnight as indicated. A 4 h serumdeprivation period preceded stimulation with 50 ng/ml VEGF for 15 min. For the activation of FAK and RAFTK/Pyk2, cells were serum starved overnight and stimulated with 100 ng/ml VEGF for 2 min. Blotting conditions were as previously described (Meadows et al., 2001) . Reprobes were done for all blots and no changes were observed in total levels of any protein analysed; to minimize figure size, only one reprobe is shown per figure.
Cell migration
Tissue culture inserts with 8 mm pore polycarbonate membranes (Costar, Corning, NY, USA) were coated with 10 mg/ml collagen followed by incubation with 1% BSA to block nonspecific binding sites. Serum-deprived HUVECs were infected with adenovirus overnight or treated with the appropriate inhibitor for 30 min prior to seeding 5.0 Â 10 4 cells per filter. The lower chamber contained serum-free MCDB 131 in the presence or absence of 25 ng/ml VEGF, a chemotactic factor. After 4 h incubation at 371C in a humidified 5% CO 2 environment, cells were fixed in 3.7% formaldehyde. Cells were visualized by nuclear staining and the number of migrating cells was quantified using automated counting with ImagePro Plus (Media Cybernetics), as described (Meadows et al., 2001) . Data presented are the average of six independent fields7s.e.m. of one representative experiment performed in duplicate transwells (three fields per transwell). Each experiment was performed two additional times.
